

# Pharmacovigilance Workshop January 26, 2007

Institute of Population Health

R. Samuel McLaughlin Centre for Population  
Health Risk Assessment

PAHO/WHO Collaborating Centre in Population  
Health Risk Assessment

**Risk Sciences International (RSI)**

Université d'Ottawa | University of Ottawa



uOttawa

L'Université canadienne  
Canada's university



uOttawa.ca

# Background and Objectives

## Background

Although all drugs licensed for sale are subject to rigorous pre market review, some of the risks associated with their use may not be identified prior to their introduction into marketplace. A comprehensive post-market surveillance system is therefore an essential component of any overall drug product risk assessment program.

## Objectives

Understand the sources of data and risk assessment tools currently available to assess the safety of marketed health products and to explore the role of academia in pharmacovigilance in Canada.

# Pharmacovigilance Workshop Program

- Health Canada
  - ADR Reporting and Signal Detection
  - Future Directions Review Post-Market Safety Data
  - Risk Communication for Marketed Health Products
- Institute of Medicine Report “The Future of Drug Safety”
- WHO Programme for International Drug Monitoring
- Maternal and Child Health Drug Safety
- Pharmacoepidemiology
- ADR Data Mining Tools
- HealthFacts Datawarehouse and Active Pharmacovigilance
- Panel Discussion “Role of Academia in Pharmacovigilance in Canada”
- Workshop Summary